Volume 12 Issue 12
COMPARISON OF THE IMPACT OF RIVAROXABAN AGAINST ASPIRIN ON STROKE RECURRENCE IN PATIENTS HAVING A HISTORY OF ATRIAL CARDIOMYOPATHY AND UNKNOWN STROKE
1Rashid Usman, 2Waqas Gulzar, 3Khalida Ajmal, 4Husnain Hashim, 5Shandana Altaf, 6Muhammad Shuaib, 7Muhammad Kashif Habib, 8Fahmida Khatoon, 9Kashif Lodhi
1Fauji Foundation Hospital, Rawalpindi,
2Mayo Hospital Lahore,
3Wah Medical College Wah Cantt.
4Fauji Foundation Hospital Rawalpindi,
5Khyber Medical College, Peshawar,
6Mohiuddin Teaching Hospital, Mirpur-AJK
7Saidu group of Teaching Hospital, Swat-Pakistan
8College of Medicine, University of Hail-Saudi Arabia
9Food and Environmental Sciences. Università Politécnica delle Marche Via Brecce Bianche 10, 60131 Ancona-Italy
Abstract:
Background: Cryptogenic strokes, the majority of which are brought on by an embolic mechanism, are a subset of ischemic stroke that affects around 25% of all patients. In people with a history of cryptogenic or left atrial cardiomyopathy and unknown stroke who are on anticoagulant therapy, rivaroxaban may reduce the chance of having another stroke compared to aspirin.
Methods: The effectiveness and tolerability of rivaroxaban and aspirin in preventing recurrent stroke in individuals with a history of left atrial cardiomyopathy and cryptogenic stroke were compared in this cross- sectional investigation.
Results: The odds ratio for stroke recurrence with aspirin treatment was 11 times higher than with rivaroxaban therapy, even after controlling for other factors such as age, gender, hypertension, and diabetes with the p-value of 0.038 and 95% confidence interval range of 1.39 to 113.08 and OR value of 11.35.
Conclusion: In individuals with a history of unknown etiology stroke and left atrial cardiomyopathy, rivaroxaban was more effective than aspirin at preventing recurrent stroke.
Keywords: Atrial cardiomyopathy; Aspirin; Stroke
